Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Assets: 2010-2024

Historic Assets for Iovance Biotherapeutics (IOVA) over the last 10 years, with Dec 2024 value amounting to $910.4 million.

  • Iovance Biotherapeutics' Assets was N/A to $904.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $904.9 million, marking a year-over-year change of. This contributed to the annual value of $910.4 million for FY2024, which is 16.67% up from last year.
  • Iovance Biotherapeutics' Assets amounted to $910.4 million in FY2024, which was up 16.67% from $780.4 million recorded in FY2023.
  • Iovance Biotherapeutics' Assets' 5-year high stood at $910.4 million during FY2024, with a 5-year trough of $780.4 million in FY2023.
  • Over the past 2 years, Iovance Biotherapeutics' median Assets value was $845.4 million (recorded in 2023), while the average stood at $845.4 million.
  • Data for Iovance Biotherapeutics' Assets shows a peak YoY climbed of 16.67% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Iovance Biotherapeutics' Assets stood at $780.4 million in 2023, then rose by 16.67% to $910.4 million in 2024.